Antibiotic resistance among Escherichia coli urinary isolates and their susceptibility to clove essential oil

Michał Dąbrowski, Monika Sienkiewicz, Hanna Zielińska-Bliźniewska, Marta Dąbrowska, Małgorzata Seredyńska, Ewa Kochan

Abstract


Escherichia coli is a Gram-negative, facultatively anaerobic, rod-shaped, coliform bacterium, which is a primary cause of urinary tract infections. Resistance to antibiotics has become a particular problem in recent decades. Consequently, there is an unmet need for new therapeutic options. It has been observed that essential oils have bactericidal effects. The antimicrobial susceptibility testing for Escherichia coli isolates obtained from urine of patients with urinary tract infections was determined via disk diffusion method according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2015). Essential oil from clove – Syzygium aromaticum (L.) Merill et L.M. (Myrtaceae) was analyzed by GC-FID-MS. Minimal Inhibitory Concentration (MIC) and Minimal Bactericidal Concentration (MBC) were detected by using the micro-dilution broth method. Escherichia coli clinical isolates are characterized by high resistance to ampicillin, amoxicillin with clavulanic acid, norfloxacin, trimethoprim/sulfamethoxazole, tetracycline, tobramycin and ticarcillin. Clove oil possesses strong inhibiting and killing properties against E. coli isolates, among them the ones resistant to recommended antibiotics. The results of this study highlight the need for testing the efficacy of new agents to inactivate bacteria in clinical settings.


Keywords


Escherichia coli, clove oil, urinary tract infections

Full Text:

PDF

References


Adams R.P. 2007. Identification of Essential Oil Components by Gas Chromatography/Mass Spectroscopy. 4th edition. Allured Publishing Corporation, Carol Stream, IL, USA.

Ahmad A., Shaheen A., Owais M., Gaurav S.S. 2013. Microbial Pathogens and Strategies for Combating Them: Science, Technology and Education. Méndez-Vilas A., Formatex Research Center, Badajoz.

Bentley R., Meganathan R. 1982. Biosynthesis of vitamin K (menaquinone) in bacteria. Microbiol. Rev. 46(3): 241–80.

Czaja C.A., Scholes D., Hooton, T.M., Stamm W.E. 2007. Population-based epidemiologic analysis of acute pyelonephritis. Clin. Infect. Dis. 45: 273–280.

Draft global action plan on antimicrobial resistance. Report by the WHO Secretariat. Geneva, Switzerland: World Health Organization, 2015.

Escherichia coli. CDC National Centre for Emerging and Zoonotic Infectious Diseases. Retrieved 2012-10-02.

European Pharmacopoeia. 2014. 8th ed., Council of Europe, Strasbourg.

Fagere Z.O., Al Magboul A.Z. 2016. Antibacterial activity of clove oil against some microorganisms at Khartoum State. Adv. Med. Plant Res. 4(4): 122–128.

Flores-Mireles A. L., Walker J. N., Caparon M., Hultgren S. J. 2015. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 13: 269–284.

Fu Y., Zu Y., Chen L., Shi X., Wang Z., Sun S., Efferth T. 2007. Antimicrobial activity of clove and rosemary essential oils alone and in combination. Phytother. Res. 21(10): 989–994.

Grabe M., Bartoletti R., Johansen T.E.B., Cai T., Cek M., Koves B., Naber K.G., Pickard R.S., Tenke P., Wagenlehner F. Wullt B. EAU guidelines on urological infections. European Association of Urology Web Site. http://uroweb.org/guideline/urological-infections/ Updated 2015.

Guénette S.A., Ross A., Marier J.F., Beaudry F., Vachon P. 2007. Pharmacokinetics of eugenol and its effects on thermal hypersensitivity in rats. Eur. J. Pharm. 562(1–2): 60–67.

H udault S., Guignot J., Servin A.L. 2001. Escherichia coli strains colonising the gastrointestinal tract protect germfree mice against Salmonella typhimurium infection. Gut. 49(1): 47–55.

Johansen T.E.B., Botto H., Cek M., Grabe M., Tenke P., Wagenlehner F.M.E., Naber K.G. 2011. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int. J. Antimicrob. Agents. 38: 64–70.

Joulain D., König W.A. 1998. The Atlas of Spectral Data of Sesquiterpene Hydrocarbons. E.B.-Verlag, Hamburg.

Kildeaa M.A., Allanb G.L., Kearney R.E. 2004. Accumulation and clearance of the anaesthetics clove oil and AQUI-S from the edible tissue of silver perch (Bidyanus bidyanus). Aquacult. 232: 265–77.

Lane D.R., Takhar S.S. 2011. Diagnosis and management of urinary tract infection and pyelonephritis. Emerg. Med. Clin. North Am. 29(3): 539–52.

Lawless J. 1995. The Illustrated Encyclopaedia of Essential Oils.

Micali S., Isgro G., Bianchi G., Micali N., Calapi G., Navarra M. 2014. Cranberry and recurrent cystitis: More than marketing? Crit. Rev. Food Sci. Nutr. 54: 1063–1075.

Naber K.G., Schito G., Botto H., Palou J., Mazzei T. 2008. Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy. Eur. Urol. 54: 1164–1178.

Nicolle L.E., Bradley S., Colgan R., Rice J.C., Schaeffer A., Hooton T.M. 2005. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin. Infect. Dis. 40: 643–654.

Polish Pharmacopeia IX. 2011. 9th ed., Polish Pharmaceutical Society, Warsaw.

Saeed S., Tariq P. 2008. In vitro antibacterial activity of clove against Gram-negative bacteria. Pak. J. Bot. 40: 2157–216.

Salvatore S., Cattoni E., Siesto G., Serai M., Sorice P., Torella M. 2011. Urinary tract infections in women. Eur. J. Obstet. Gynecol. Reprod. Biol. 156(2): 131–136.

Singleton P. 1999. Bacteria in Biology, Biotechnology and Medicine (5th ed.). Wiley. pp. 444–454.

Smelov V., Naber K., Bjerklund Johansen T. E. 2016. Improved classification of urinary tract infection: future considerations. Eur. Urol. Suppl. 15: 71–80.

Sofia P.K., Prasad R., Vijay V.K., Srivastava A.K. 2007. Evaluation of antibacterial activity of Indian spices against common foodborne pathogens. Int. J. Food Sci. Technol. 42(8):910–915.

Z acché M.M., Giarenis I. 2016. Therapies in early development for the treatment of urinary tract inflammation. Exp. Opin. Investig. Drugs 25: 531–540.




DOI: http://dx.doi.org/10.17951/c.2016.71.2.41
Data publikacji: 2018-02-21 08:04:03
Data złożenia artykułu: 2017-09-23 19:22:47

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Monika Sienkiewicz

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.